NCT00369603View on ClinicalTrials.gov

Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

PHASE4TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

November 30, 2007

Conditions
Alzheimer's Disease
Interventions
DRUG

Razadyne ER

4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER

DRUG

Aricept

8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept

Trial Locations (1)

27705

Joseph & Kathleen Bryan Alzheimer's Disease Research Unit, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Ortho-McNeil Neurologics, Inc.

INDUSTRY

lead

Duke University

OTHER

NCT00369603 - Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients | Biotech Hunter | Biotech Hunter